DelveInsight's Surgical Site Infections Pipeline Insight 2025

According to DelveInsight's evaluation, the global Surgical Site Infections pipeline features over 5 key companies actively advancing over 5 Surgical Site Infections treatment therapies. This includes analysis of clinical trials, therapies, mechanisms of action, administration routes, and developmental progress by DelveInsight.

The Surgical Site Infections Pipeline report includes thorough commercial and clinical evaluations of pipeline products from the preclinical development stage through to marketed products. It also provides detailed drug descriptions, covering the mechanism of action, clinical trials, NDA approvals (if applicable), and product development activities such as technology, partnerships, mergers and acquisitions, funding, designations, and other relevant details.

DelveInsight's "Surgical Site Infections Pipeline Insight, 2025" report highlights extensive insights into the current clinical development landscape and growth opportunities in the Surgical Site Infections Market.

Key Highlights from the Surgical Site Infections Pipeline Report: https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

• Organizations worldwide are actively pursuing innovative Surgical Site Infections treatment therapies, achieving notable progress in recent years.

• Surgical Site Infections firms involved in the treatment sector include Destiny Pharma plc, MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc, and others, all developing therapies for Surgical Site Infections management.

• Promising Surgical Site Infections therapies across various clinical trial phases include Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ong, E-101, and others, anticipated to significantly influence the Surgical Site Infections market soon.

• In August 2025, Mayo Clinic scientists developed an artificial intelligence (AI) tool capable of precisely detecting surgical site infections (SSIs) from patient-provided postoperative wound photos. Featured in Annals of Surgery, this represents a major leap in remote patient surveillance and infection prevention.

• In June 2025, PolyPid Ltd. (Nasdaq: PYPD), a biopharmaceutical firm in the late stages focused on improving surgical results, shared encouraging topline data from its pivotal SHIELD II Phase 3 trial of D-PLEX100. This treatment, aimed at preventing surgical site infections (SSIs) in individuals undergoing abdominal colorectal surgery with extensive incisions, has also earned Fast Track status from the FDA.

Surgical Site Infections Overview Surgical Site Infections refer to infections that develop at the surgical incision site or in nearby tissues after a procedure. These can vary from surface-level infections impacting the skin and underlying tissue to more serious ones involving deeper structures like muscles and organs.

Obtain a Free Sample PDF Report for more on Surgical Site Infections Pipeline Therapeutic Assessment-  https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Emerging Surgical Site Infections Drugs in Various Clinical Development Stages Include:

• XF-73: Destiny Pharma plc

• Ciprodiazole: MinaPharm Pharma

• DFA-02: Duke Clinical Research

• ZuraPrep: Zurex Pharma, Inc.

• Ertapenem: Merck Sharp & Dohme LLC

• D-PLEX: PolyPid Ltd.

• Dalbavancin: Durata Therapeutics

• BACTROBAN® Nasal ong: Lindenhofgruppe AG

• E-101: Veristat, Inc

Surgical Site Infections Route of Administration The Surgical Site Infections pipeline report assesses pipeline drugs by administration method. Products are classified under different routes such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Surgical Site Infections Molecule Type Surgical Site Infections products are grouped by molecule categories like

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Surgical Site Infections Pipeline Therapeutics Assessment

• Surgical Site Infections Evaluation by Product Category

• Surgical Site Infections by Stage and Product Category

• Surgical Site Infections Evaluation by Administration Route

• Surgical Site Infections by Stage and Administration Route

• Surgical Site Infections Evaluation by Molecule Category

• Surgical Site Infections by Stage and Molecule Category

DelveInsight's Surgical Site Infections Report encompasses over 5 products in different clinical development phases, including

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Administration Route

Additional details on Surgical Site Infections products are available in the report. Download the Surgical Site Infections pipeline report to explore emerging therapies further https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Leading Companies in the Surgical Site Infections Therapeutics Market Include: Major firms advancing Surgical Site Infections therapies are - Becton, Dickinson and Company, 3M Company, Biomerieux SA, Getinge Group, and Johnson & Johnson, among others.

Surgical Site Infections Pipeline Analysis: The Surgical Site Infections pipeline report offers insights into

• In-depth information on companies creating therapies for Surgical Site Infections, with the total therapies per company.

• Segmentation of various therapeutic candidates into early, mid, and late development stages for Surgical Site Infections treatment.

• Surgical Site Infections key companies engaged in targeted therapy development, including active and inactive (dormant or terminated) projects.

• Surgical Site Infections drugs in development, based on development stage, administration route, target receptor, monotherapy or combination approach, mechanism of action, and molecule type.

• Comprehensive review of partnerships (corporate-corporate and corporate-academic), licensing arrangements, and funding for advancing the Surgical Site Infections market. The report draws from data sourced from proprietary databases, company/university sites, clinical trial databases, conferences, SEC filings, investor presentations, and press releases from company/university websites and specialized third-party sources.

Download a Sample PDF Report to learn more about Surgical Site Infections drugs and therapies https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Surgical Site Infections Pipeline Market Drivers

• Increasing surgical procedures and an aging population, coupled with heightened awareness of hospital-acquired infections and rising cases of such infections, are key factors propelling the Surgical Site Infections Market.

Surgical Site Infections Pipeline Market Barriers

• Nevertheless, insufficient knowledge about infection prevention strategies, challenges in pinpointing infection locations, and other issues are hindering growth in the Surgical Site Infections Market.

Scope of Surgical Site Infections Pipeline Drug Insight

• Coverage: Global

• Key Surgical Site Infections Companies: Destiny Pharma plc, MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc, and others

• Key Surgical Site Infections Therapies: Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ong, E-101, and others

• Surgical Site Infections Therapeutic Assessment: Current marketed and emerging Surgical Site Infections therapies

• Surgical Site Infections Market Dynamics: Drivers and barriers in the Surgical Site Infections market

About Us

DelveInsight is a premier healthcare market research and advisory firm delivering top-tier market intelligence and analysis to guide strategic business choices. With a skilled team of industry specialists and profound expertise in life sciences and healthcare, we provide tailored research services and insights worldwide. Reach out to us for precise, timely, and reliable data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com